|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TM2D1 |
Gene summary for TM2D1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TM2D1 | Gene ID | 83941 |
| Gene name | TM2 domain containing 1 | |
| Gene Alias | BBP | |
| Cytomap | 1p31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | Q9BX74 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83941 | TM2D1 | LZE2T | Human | Esophagus | ESCC | 8.40e-05 | 5.10e-01 | 0.082 |
| 83941 | TM2D1 | LZE3D | Human | Esophagus | HGIN | 4.30e-02 | 4.51e-01 | 0.0668 |
| 83941 | TM2D1 | LZE4T | Human | Esophagus | ESCC | 4.61e-19 | 3.35e-01 | 0.0811 |
| 83941 | TM2D1 | LZE5T | Human | Esophagus | ESCC | 1.35e-04 | 4.89e-01 | 0.0514 |
| 83941 | TM2D1 | LZE7T | Human | Esophagus | ESCC | 6.40e-05 | 6.98e-01 | 0.0667 |
| 83941 | TM2D1 | LZE8T | Human | Esophagus | ESCC | 1.29e-15 | 3.75e-01 | 0.067 |
| 83941 | TM2D1 | LZE20T | Human | Esophagus | ESCC | 1.88e-12 | 4.70e-01 | 0.0662 |
| 83941 | TM2D1 | LZE22D1 | Human | Esophagus | HGIN | 1.41e-05 | 1.50e-01 | 0.0595 |
| 83941 | TM2D1 | LZE22T | Human | Esophagus | ESCC | 2.67e-06 | 4.47e-01 | 0.068 |
| 83941 | TM2D1 | LZE24T | Human | Esophagus | ESCC | 1.06e-31 | 8.90e-01 | 0.0596 |
| 83941 | TM2D1 | LZE6T | Human | Esophagus | ESCC | 5.14e-03 | 2.37e-01 | 0.0845 |
| 83941 | TM2D1 | P1T-E | Human | Esophagus | ESCC | 1.08e-06 | 4.43e-01 | 0.0875 |
| 83941 | TM2D1 | P2T-E | Human | Esophagus | ESCC | 2.30e-35 | 7.55e-01 | 0.1177 |
| 83941 | TM2D1 | P4T-E | Human | Esophagus | ESCC | 3.46e-31 | 5.41e-01 | 0.1323 |
| 83941 | TM2D1 | P5T-E | Human | Esophagus | ESCC | 6.86e-25 | 4.45e-01 | 0.1327 |
| 83941 | TM2D1 | P8T-E | Human | Esophagus | ESCC | 1.66e-50 | 9.18e-01 | 0.0889 |
| 83941 | TM2D1 | P9T-E | Human | Esophagus | ESCC | 4.71e-20 | 3.85e-01 | 0.1131 |
| 83941 | TM2D1 | P10T-E | Human | Esophagus | ESCC | 1.26e-51 | 9.77e-01 | 0.116 |
| 83941 | TM2D1 | P11T-E | Human | Esophagus | ESCC | 3.10e-17 | 5.51e-01 | 0.1426 |
| 83941 | TM2D1 | P12T-E | Human | Esophagus | ESCC | 3.54e-33 | 6.03e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TM2D1 | SNV | Missense_Mutation | c.409N>C | p.Asp137His | p.D137H | Q9BX74 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A2DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR | |
| TM2D1 | SNV | Missense_Mutation | rs369821446 | c.341N>A | p.Arg114Gln | p.R114Q | Q9BX74 | protein_coding | tolerated(0.08) | possibly_damaging(0.462) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| TM2D1 | SNV | Missense_Mutation | c.59N>A | p.Val20Asp | p.V20D | Q9BX74 | protein_coding | deleterious_low_confidence(0.01) | benign(0.011) | TCGA-DM-A28A-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| TM2D1 | SNV | Missense_Mutation | c.341G>T | p.Arg114Leu | p.R114L | Q9BX74 | protein_coding | tolerated(0.06) | benign(0.396) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TM2D1 | SNV | Missense_Mutation | c.10G>T | p.Ala4Ser | p.A4S | Q9BX74 | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-AX-A06L-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TM2D1 | SNV | Missense_Mutation | novel | c.171N>G | p.Ile57Met | p.I57M | Q9BX74 | protein_coding | tolerated(0.16) | benign(0.001) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TM2D1 | SNV | Missense_Mutation | c.490N>T | p.Asp164Tyr | p.D164Y | Q9BX74 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
| TM2D1 | SNV | Missense_Mutation | novel | c.253N>A | p.Ala85Thr | p.A85T | Q9BX74 | protein_coding | deleterious(0.01) | benign(0.1) | TCGA-EY-A2OM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
| TM2D1 | SNV | Missense_Mutation | rs369821446 | c.341G>A | p.Arg114Gln | p.R114Q | Q9BX74 | protein_coding | tolerated(0.08) | possibly_damaging(0.462) | TCGA-38-4632-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | gemcitabine | PD |
| TM2D1 | SNV | Missense_Mutation | c.278C>G | p.Ser93Cys | p.S93C | Q9BX74 | protein_coding | tolerated(0.18) | benign(0.215) | TCGA-50-5044-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |